One million haemopoietic stem-cell transplants: a retrospective observational study.

BACKGROUND The transplantation of cells, tissues, and organs has been recognised by WHO as an important medical task for its member states; however, information about how to best organise transplantation is scarce. We aimed to document the activity worldwide from the beginning of transplantation and search for region adapted indications and associations between transplant rates and macroeconomics. METHODS Between Jan 1, 2006, and Dec 31, 2014, the Worldwide Network for Blood and Marrow Transplantation collected data for the evolution of haemopoietic stem-cell transplantation (HSCT) activity and volunteer donors in the 194 WHO member states. FINDINGS 953,651 HSCTs (553,350 [58%] autologous and 400,301 [42%] allogeneic) were reported by 1516 transplant centres from 75 countries. No transplants were done in countries with fewer than 300,000 inhabitants, a surface area less than 700 km(2), and a gross national income per person of US$1260 or lower. Use of HSCT increased from the first transplant in 1957 to almost 10,000 by 1985. We recorded a cumulative total of about 100,000 transplants by 1995, and an estimated 1 million by December, 2012. Unrelated donor registries contributed 22·3 million typed volunteer donors and 645,646 cord blood products by 2012. Numbers of allogeneic HSCTs increased in the past 35 years with no signs of saturation (R(2)=0·989). Transplant rates were higher in countries with more resources, more transplant teams, and an unrelated donor infrastructure. INTERPRETATION Our findings show achievements and high unmet needs and give guidance for decisions; to grant access for patients, to provide a donor infrastructure, and to limit overuse by defining risk and region adapted indications for HSCT as an efficient and cost-effective approach for life-threatening, potentially curable diseases. FUNDING Funding for this study was indirectly provided by support of the WBMT.

[1]  Y. Kodera,et al.  Challenges and opportunities for HSCT outcome registries: perspective from international HSCT registries experts , 2014, Bone Marrow Transplantation.

[2]  J. Sierra,et al.  Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia , 2000, The Lancet.

[3]  D. Higgs A new dawn for stem-cell therapy. , 2008, The New England journal of medicine.

[4]  R. Schlenk,et al.  The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach , 2012, Nature Reviews Clinical Oncology.

[5]  R. Brand,et al.  Use of the quality management system “JACIE” and outcome after hematopoietic stem cell transplantation , 2014, Haematologica.

[6]  C. Begg,et al.  Marrow transplantation for acute nonlymphoblastic leukemia. , 1980, The New England journal of medicine.

[7]  A. Krishnan,et al.  Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  R. Raijmakers,et al.  Autologous bone-marrow transplantation. , 1987, Lancet.

[9]  Edward A Copelan,et al.  Hematopoietic stem-cell transplantation. , 2006, The New England journal of medicine.

[10]  M. Pasquini,et al.  2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. , 2010, Clinical transplants.

[11]  A. Gratwohl,et al.  Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study , 2013, Haematologica.

[12]  A. Gratwohl,et al.  Changes in the use of hematopoietic stem cell transplantation: a model for diffusion of medical technology , 2010, Haematologica.

[13]  A. Carrel WHO guiding principles on human cell, tissue and organ transplantation. , 2010, Transplantation.

[14]  J. Chapman,et al.  Remuneration of hematopoietic stem cell donors: principles and perspective of the World Marrow Donor Association. , 2011, Blood.

[15]  N. Sacchi,et al.  Standards, regulations and accreditation for registries involved in the worldwide exchange of hematopoietic stem cell donors and products , 2010, Bone Marrow Transplantation.

[16]  C. McCabe,et al.  Funding the Unfundable , 2012, PharmacoEconomics.

[17]  Fumito Ito,et al.  Current Status and Future Directions , 2013 .

[18]  M. Pasquini,et al.  2013 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. , 2013, Clinical transplants.

[19]  S. W. H. Assembly WHO Guiding Principles on Human Cell, Tissue and Organ Transplantation , 2010, Cell and Tissue Banking.

[20]  A. Velardi,et al.  The EBMT activity survey: 1990–2010 , 2012, Bone Marrow Transplantation.

[21]  J. Pidala,et al.  Practice variation in physician referral for allogeneic hematopoietic cell transplantation , 2012, Bone Marrow Transplantation.

[22]  Dirk J Schaefer,et al.  Engineered autologous cartilage tissue for nasal reconstruction after tumour resection: an observational first-in-human trial , 2014, The Lancet.

[23]  J. Epstein Best practices in regulation of blood and blood products. , 2012, Biologicals : journal of the International Association of Biological Standardization.

[24]  A. Gratwohl,et al.  Hematopoietic stem cell transplantation: a global perspective. , 2010, JAMA.

[25]  P. Linden History of solid organ transplantation and organ donation. , 2009, Critical care clinics.

[26]  F. Appelbaum Hematopoietic cell transplantation for non-Hodgkin's lymphoma: yesterday, today, and tomorrow. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  E. Thomas Marrow transplantation for nonmalignant disorders. , 1978, The New England journal of medicine.

[28]  J. Kurtzberg,et al.  Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. , 1989, The New England journal of medicine.

[29]  M. Pasquini,et al.  Lifetime probabilities of hematopoietic stem cell transplantation in the U.S. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  B. Storer,et al.  Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. , 2001, The New England journal of medicine.

[31]  A. Efrat The Politics of Combating the Organ Trade: Lessons From the Israeli and Pakistani Experience , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[32]  E. Stadtmauer,et al.  High-dose chemotherapy and autologous hematopoietic stem cell transplantation for metastatic breast cancer: a therapy whose time has passed , 2006, Bone Marrow Transplantation.

[33]  Michael Boeckh,et al.  Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.

[34]  H. Einsele,et al.  Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009 , 2010, Bone Marrow Transplantation.

[35]  A. van Leeuwen,et al.  Bone Marrow Donors Worldwide: a successful exercise in international cooperation. , 1994, Bone marrow transplantation.

[36]  E. E. Osgood,et al.  APLASTIC ANEMIA TREATED WITH DAILY TRANSFUSIONS AND INTRAVENOUS MARROW; CASE REPORT , 1939 .

[37]  Thomas Eschenhagen,et al.  Cardiac tissue engineering: state of the art. , 2014, Circulation research.

[38]  R. Wittes,et al.  Autologous bone marrow transplantation. Current status and future directions. , 1989, Annals of internal medicine.

[39]  E. Thomas,et al.  Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. , 1957, The New England journal of medicine.

[40]  M. Bortin A COMPENDIUM OF REPORTED HUMAN BONE MARROW TRANSPLANTS , 1970, Transplantation.

[41]  M. Sorror Impacts of pretransplant comorbidities on allogeneic hematopoietic cell transplantation (HCT) outcomes. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[42]  MartinIvan,et al.  The Survey on Cellular and Engineered Tissue Therapies in Europe in 2013 , 2016 .

[43]  B. Hammer,et al.  OXYGEN PERSUFFLATION INCREASES PANCREATIC ATP LEVELS AND VIABLE ISLET YIELD FOLLOWING 24 HOURS PRESERVATION COMPARED WITH THE TWO-LAYER METHOD (TLM): 1196 , 2010 .

[44]  K. Schulman,et al.  Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer , 2003, Bone Marrow Transplantation.

[45]  S. Tunis,et al.  Coverage options for promising technologies: Medicare's 'coverage with evidence development'. , 2006, Health affairs.

[46]  R Storb,et al.  Bone-marrow transplantation (second of two parts). , 1975, The New England journal of medicine.

[47]  A. Gratwohl The EBMT risk score , 2012, Bone Marrow Transplantation.

[48]  Ivan Martin,et al.  The survey on cellular and engineered tissue therapies in Europe in 2009. , 2010, Tissue engineering. Part A.

[49]  J. Klein,et al.  Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States. , 2005, Blood.